Cannabinol, or CBN, has rapidly ascended to prominence in the wellness industry. Often marketed as a "natural" and "gentle" alternative to conventional sleep aids, it has become a staple in the booming cannabis-adjacent supplement market. From CBD-adjacent gummies and specialized tinctures to bedtime capsules, the compound is being sold to millions of consumers seeking a reprieve from insomnia and restless nights. However, a significant new study from the University of Connecticut is casting a long shadow over this trend, suggesting that the widely available compound may carry latent risks that consumers—and regulators—have yet to fully grapple with.
The research, published in the November issue of the academic journal Drug and Alcohol Dependence, indicates that repeated exposure to CBN may lead to physical dependence in mammalian models. These findings serve as a stark reminder that even substances derived from plants are pharmacologically active and that their widespread, unregulated use warrants a more cautious approach. As the market for minor cannabinoids continues to outpace the scientific community’s ability to conduct long-term safety studies, experts are urging the public to consider the potential for habituation and other unintended physiological consequences.
Popular Sleep Aid Shows Effects Similar to THC
CBN is a naturally occurring cannabinoid found in the Cannabis sativa plant. While it is often grouped with its more famous counterparts—THC (tetrahydrocannabinol), which is known for its psychoactive properties, and CBD (cannabidiol), which is widely used for non-intoxicating wellness purposes—CBN occupies a unique space in the public imagination. It is frequently marketed as the "sleepy" cannabinoid, a perception bolstered by its chemical origin: as THC ages and degrades, it eventually breaks down into CBN.
Because of this, many consumers assume that CBN is inherently mild, offering the therapeutic benefits of cannabis without the intensity of THC. However, the study conducted at the University of Connecticut suggests that this distinction may be more nuanced—and perhaps more dangerous—than previously believed. Steven Kinsey, a professor in UConn’s Elisabeth DeLuca School of Nursing, notes that the ubiquitous presence of these products in modern commerce is outpacing the scientific understanding of their long-term impact.
"CBN is everywhere right now," says Kinsey. "Gummies, tinctures, capsules, and it’s marketed as a safe, herbal sleep supplement. Our findings suggest consumers should be aware that repeated use may carry risks that have not been adequately explored by the manufacturers pushing these products."
In the laboratory setting, researchers observed that mice administered CBN twice daily over a three-day period began to exhibit clear signs of tolerance. This means that as the treatment continued, the animals required more of the compound to achieve the same effect, a hallmark characteristic of substances that can lead to physical dependence. More concerning, however, were the symptoms displayed when the administration of CBN was abruptly stopped. The mice exhibited physical withdrawal markers, including involuntary head twitching and paw fluttering—movements that share striking parallels with the physical shaking and distress observed in human drug withdrawal.
Perhaps the most significant revelation from the study is the biological overlap between CBN and THC. In a secondary experiment, researchers trained mice to recognize the psychoactive effects of THC. When these same mice were later exposed to CBN, they responded as if they had been given THC. This suggests that, at least within the biological systems of the mice, the two compounds produce remarkably similar subjective effects. These results imply that CBN is not merely a benign "herbal" supplement but a compound that interacts with the same receptor systems in the brain that are responsible for the development of THC dependence.
Scientists Raise Concerns About CBN Sleep Supplements
The implications of this research are magnified by the current, largely unregulated state of the minor cannabinoid market. While the pharmaceutical industry is bound by strict, multi-year clinical trial requirements before a sleep aid can reach the market, the supplement industry often operates under a different set of rules. Consequently, consumers are often left to navigate an influx of therapeutic claims with little to no guidance on long-term safety profiles.
Olivia Vanegas, a Ph.D. candidate at UConn and the lead author of the study, expresses frustration with the current landscape of the industry. "The marketing of minor cannabinoids is pretty wild right now," she explains. "There are so many therapeutic claims about these drugs, but we really don’t know much about their potential risks, especially with repeated use."
The concern is rooted in historical precedent. Over the last century, the medical community has seen numerous sleep aids—once heralded as breakthroughs—eventually revealed to carry severe risks of addiction, dependency, or debilitating side effects once they were used by the general population over long durations. With CBN, researchers are currently operating in a knowledge vacuum. There is no comprehensive understanding of how CBN impacts the architecture of human sleep, nor is there data on whether the dosages commonly found in off-the-shelf supplements are sufficient to foster addiction in human users over months or years of regular nightly use.
The lack of longitudinal human data is the most significant hurdle. While the UConn study provides a vital warning, it was conducted on mice, which are standard models for initial pharmacological testing but cannot perfectly replicate the complex psychological and physiological experience of a human being. The study does not establish definitively that CBN causes dependence in humans; rather, it highlights an urgent need for human-centric clinical research that examines frequent, high-dose, and long-term consumption patterns.
Potential Benefits Come With Unanswered Safety Questions
It is important to note that the study did not dismiss the therapeutic potential of CBN entirely. The researchers identified that the compound does possess legitimate anti-inflammatory properties. Intriguingly, these effects were observed at lower doses that did not appear to trigger the same psychoactive or dependence-related responses, hinting that there may be a therapeutic "sweet spot" for the compound if it were to be properly regulated and dosed.
However, the research also uncovered a troubling secondary effect: immunosuppression. During a simulated bacterial challenge, the researchers observed that CBN reduced the ability of the subjects’ immune systems to defend against infection. This raises the possibility that chronic use of the supplement could theoretically leave users more vulnerable to opportunistic illnesses, much like how a minor, neglected injury can become a gateway for systemic infection.
These conflicting signals—the potential for anti-inflammatory relief versus the risks of immune suppression and physical dependence—underscore the complexity of the substance. Scientists are now calling for a more measured approach to the use of minor cannabinoids. Before CBN can be considered a safe, standard treatment for sleep disorders, the scientific community must map out the dose-response relationship and identify the threshold at which the compound’s risks outweigh its potential for relief.
As it stands, the research serves as a cautionary tale for the wellness industry and the consumers who support it. The allure of a "natural" fix for the modern epidemic of sleep deprivation is powerful, but the UConn study suggests that "natural" is not synonymous with "harmless." Until large-scale, rigorous human trials can provide a clearer picture of how CBN behaves in the body over extended periods, the findings suggest that the most prudent path for the public is to approach these supplements with significant skepticism.
"CBN may still have therapeutic value," Kinsey concludes, emphasizing that the goal is not to demonize the compound but to understand it. "But until we know more about dosing and long-term effects, the message for consumers is simple: buyer beware."
